Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health Inc. (NYSE:HIMS) has decided to cease offering its compounded semaglutide pill.Hims & Hers Explains Its DecisionHims & Hers' decision to stop offering the $49 version of Novo Nordisk A/S' (NYSE:NVO) Wegovy comes days after the company launched it."Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment," the company said in a post on X ...